2014-05-05T12:02:09-05:00 2013-12-31 042088368 GRAY GRAY & GRAY LLP 34 SOUTHWEST PARK WESTWOOD MA 020901548 990 2013-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION CURE ALZHEIMER'S FUND ALZH 7812373800 34 WASHINGTON ST NO 200 WELLESLEY MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2014-03-17 1 RICHARD D TARDIFF P00154902 7814070300 2014-03-03 2013 2015-11-30 17:44:51Z TIMOTHY W ARMOUR 21 SUNSET ROAD WESTON MA 02493 7819556 0 X WWW.CUREALZ.ORG X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTRHOPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 6 5 6 25 0 0 9103453 6388347 0 0 11166 -15933 13447 10000 9128066 6382414 3341898 4576000 0 0 608099 654122 0 0 283759 1034405 1158912 4984402 6389034 4143664 -6620 8871081 8947500 176842 260402 8694239 8687098 FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 4576000 4576000 IN 2013, CURE ALZHEIMER'S FUND FUNDED NINETEEN RESEARCH PROJECTS AT ELEVEN LEADING ACADEMIC ALZHEIMER'S RESEARCH LABORATORIES IN THE UNITED STATES. EACH OF THESE GRANTS HAD THE OBJECTIVE OF LEARNING MORE ABOUT THE ORIGINS OF THE DISEASE, UNDERSTANDING MORE ABOUT THE PROGRESSION OF THE PATHOLOGY OR DEVELOPING DRUGS TO STOP THE DISEASE. 838361 SUPPORT OF THE GRANTING PROCESS AND CREATING AWARENESS FOR THE NEED FOR MORE RESEARCH TOOK THE FORM OF MEETINGS OF THE RESEARCH CONSORTIUM TO REVIEW AND MODIFY CURE ALZHEIMER'S FUND'S RESEARCH AGENDA, SUPPORT OF THE SCIENTIFIC ADVISORY BOARD IN REVIEWING PROPOSALS AND MEETINGS, MAILINGS AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 250133 CURE ALZHEIMER'S FUND SERVES AS FIDUCIARY AGENT FOR A SERIES OF INDEPENDENTLY PRODUCED VIDEOS ABOUT ALZHEIMER'S DISEASE. WITH AN EXECUTIVE PRODUCER, THE ORGANIZATION RECEIVES FUNDS FROM THE METROPOLITAN LIFE FOUDNATION, DISPENSES THEM AS APPROVED BY THE EXECUTIVE PRODUCER AND REPORTS THE FINANCIAL ACTIVITY PERIODICALLY TO THE METROPOLITAN LIFE FOUNDATION. 5664494 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 22 0 6 1 0 0 0 0 0 0 0 0 X 6 5 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA AL AK AS AZ AR CA CO CT DE DC FM FL GA GU HI ID IL IN IA KS KY LA ME MH MD MI MN MS MO MT NE NV NH NJ NM NY NC ND MP OH OK OR PW PA PR RI SC SD TN TX UT VT VI VA WA WV WI WY X X X TIMOTHY W ARMOUR 7812373800 34 WASHINGTON STREET STE 200 WELLESLEY MA 02481 JEFFREY MORBY CHAIRMAN OF BOD, TREASURER 2.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 HENRY MCCANCE DIRECTOR 1.00 X 0 0 0 PHYLLIS RAPPAPORT DIRECTOR 1.00 X 0 0 0 ROBERT GREENHILL DIRECTOR 1.00 X 0 0 0 TIMOTHY W ARMOUR PRESIDENT 40.00 X X 177015 0 4759 MICHAEL F CURREN SECRETARY AND SR. VICE PRE 40.00 X 142471 0 6583 SALLY G ROSENFIELD VICE PRESIDENT 40.00 X 124924 0 6583 444410 0 17925 3 0 1 0 DAVID SHENK 216 ST JOHNS PLACE APT D BROOKLYN NY 11217 PRESENTOR/ADVISOR 190000 1 6388347 1437142 6388347 296 296 1420913 1437142 -16229 -16229 -16229 OTHER INCOME 900099 10000 10000 10000 6382414 -6229 0 296 4576000 4576000 501888 253745 125056 123087 80034 19758 37882 22394 7412 3629 2072 1711 27879 12066 8525 7288 36909 18239 9619 9051 3015 3015 125701 125701 45190 35500 1690 8000 29092 11030 18062 7976 3159 4817 42720 42720 52607 36196 11363 5048 11350 9218 932 1200 13011 13011 1945 1945 DOCUMENTARIES 250133 250133 SOCIAL MEDIA 120455 120105 350 PRINTING AND REPRODUCTI 91112 64743 2628 23741 INFORMATION AND AWARENE 69627 63676 5951 294978 190456 51463 53059 6389034 5664494 440781 283759 1575930 1076986 4626974 5383173 2626500 2467341 3320 6794 35906 32680 16009 3226 228 22120 9980 8871081 8947500 21737 45330 155105 215072 176842 260402 X 5975506 7273645 2718733 1413453 8694239 8687098 8871081 8947500 -6620 -523 0 X 0 1 X 1 0 X 3339366 4039719 4763246 9103453 6388347 27634131 3339366 4039719 4763246 9103453 6388347 27634131 9909195 17724936 20020 -5755 5084 11166 -15933 14582 -498 13447 10000 22949 27671662 0.64050 0.62690 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 43279 0 0 43279 0 PART II-B, LINE 1: PART II-B, LINE 1(I), OTHER LOBBYING ACTIVITIES: A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH. 17926 14700 3226 17980 17980 0 3226 ACCRUED EXPENSES 65072 UNEXPENDED AUTHORIZATIONS 150000 215072 X 6411335 -521 29442 28921 6382414 0 6382414 6418476 29442 29442 6389034 0 6389034 PART X, LINE 2: CAF WAS DETERMINED TO BE EXEMPT FROM FEDERAL INCOME TAX UNDER PROVISIONS OF SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE OF 1986 (IRC) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION AS DEFINED IN SECTION 509(A)(3) OF THE IRC. ACCORDINGLY, NO PROVISIONS FOR FEDERAL OR STATE INCOME TAXES ARE REQUIRED.CAF IS REQUIRED TO RECOGNIZE THE FINANCIAL STATEMENT IMPACT OF A TAX POSITION WHEN IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION. ANY INTEREST AND PENALTIES RECOGNIZED ASSOCIATED WITH A TAX POSITION WOULD BE CLASSIFIED AS CURRENT IN CAF'S FINANCIAL STATEMENTS. CURRENTLY, THE TAX YEARS ENDED DECEMBER 31, 2010, 2011, AND 2012 ARE OPEN AND SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE AND THE MASSACHUSETTS DEPARTMENT OF REVENUE. HOWEVER, CAF IS NOT CURRENTLY UNDER AUDIT NOR HAS CAF BEEN CONTACTED BY ANY OF THESE JURISDICTIONS. BASED ON THE EVALUATION OF CAF'S TAX POSITIONS, MANAGEMENT BELIEVES ALL POSITIONS TAKEN WOULD BE UPHELD UNDER AN EXAMINATION. THEREFORE, NO PROVISION FOR THE EFFECTS OF UNCERTAIN TAX POSITIONS HAS BEEN RECORDED FOR THE YEAR ENDED DECEMBER 31, 2013. 1 MIDDLE EAST AND NORTH AFRICA 0 0 GRANT AWARDED TO HADASSAH MEDICAL CENTER 100000 0 0 0 0 0 0 100000 0 100000 MIDDLE EAST AND NORTH AFRICA STEM CELL RESEARCH 100000 CHECK 1 0 0 0 0 0 0 0 PART I, LINE 2: AFTER A PRELIMINARY REVIEW OF THE SUBMITTED PROPOSAL BY THE CHAIR OF THE RESEARCH CONSORTIUM, A PROPOSAL MAY BE SENT FOR A SECOND PRELIMINARY REVIEW BY OTHER MEMBERS OF THE RESEARCH CONSORTIUM. IF THOSE PEOPLE DEEM THE PROPOSAL APPROPRIATE FOR FURTHER REVIEW, THE PRESIDENT OF CURE ALZHEIMER'S FUND SENDS THE PROPOSAL TO TWO MEMBERS OF THE SCIENTIFIC ADVISORY BOARD FOR THEIR REVIEWS. QUESTIONS OR CONCERNS BY THE REVIEWERS ARE SENT TO THE PERSON PROPOSING THE PROJECT FOR RESOLUTION. IF THE RESOLUTION IS SATISFACTORY TO THE REVIEWER(S), THE PROPOSAL IS THEN SENT TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS FOR FINAL APPROVAL. AFTER THAT APPROVAL, THE PROPOSAL IS FUNDED WITH THE CONDITIONS THAT THERE BE A MID-TERM REPORT APPROXIMATELY SIX MONTHS FROM THE TIME OF ISSUE INCLUDING PROGRESS AGAINST THE ORIGINAL OBJECTIVES; AND A FINAL REPORT DUE TWELVE MONTHS AFTER THE TIME OF ISSUE INCLUDING RESULTS MEASURED AGAINST OBJECTIVES AND A FULL FINANCIAL REPORT ON THE USE OF THE GRANT FUNDS. A PROJECT CAN BE INTERRUPTED OR RE-DIRECTED AT ANY TIME THE RESEARCH CONSORTIUM OR THE SCIENTIFIC ADVISORY BOARD BELIEVES THE PROJECT IS NOT FULFILLING ITS ORIGINAL INTENT. 1 MASSACHUSETTS GENERAL HOSPITAL MGH AGING AND RESEARCH UNIT 114 16TH STREET CHARLESTOWN MA 02129 501C3 100000 STEM CELL MASSACHUSETTS GENERAL HOSPITAL MGH AGING AND RESEARCH UNIT 114 16TH STREET CHARLESTOWN MA 02129 501C3 600000 CONTINUATION OF ALZHEIMER'S GENOME PROJECT MASSACHUSETTS GENERAL HOSPITAL MGH AGING AND RESEARCH UNIT 114 16TH STREET CHARLESTOWN MA 02129 501C3 300000 THE AMULIM PROTEIN OF DIABETES MELLITUS IS AN AMTIMICROBIAL PEPTIDE NORTHWESTERN UNIVERISTY 300 EAST SUPERIOR ST TARRY 8-713 CHICAGO IL 606113006 501C3 100000 THE ROLES OF EPS HOMOLOGY DOMAIN (EHD) PROTEINS AND SYMAPTIC ACTIVITY IN AXON TRANSPORT OF THE ALZHEIMER'S BETA-SECREASE BACE1 IN THE BRAIN UNIVERSITY OF CALIFORNIA IRVINE 2100 MEDICAL PLAZA DR IRVINE CA 92697 501C3 100000 CHARACTERIZATION OF PATHOLOGICAL SIGNIFICANCE OF A NOVEL TYPE OF VASCULAR AMYLOID UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501C3 100000 NORMALIZING ABETA SYNAPTIC DEPRESSION WITH DRUGS TARGETING PICK 1 THE UNIVERSITY OF CHICAGO 924 E 57TH STREET CHICAGO IL 60637 501C3 100000 BACE1 TRANSCYTOSIS IN ALZHEIMER'S DISEASE PATHOGENESIS MASSACHUSETTS GENERAL HOSPITAL MGH AGING AND RESEARCH UNIT 114 16TH STREET CHARLESTOWN MA 02129 501C3 750000 WHOLE GENOME SEQUENCING BRIGHAM AND WOMEN'S HOSPITAL 77 AVENUE LOUIS PASTEUR BOSTON MA 02115 501C3 126000 AB OLIGOMERS AND THE PATHOGENIC SPREAD OF TAU AGGREGATION; IMPLICATIONS FOR AD MECHANISM AND TREATMENT MASSACHUSETTS GENERAL HOSPITAL MGH AGING AND RESEARCH UNIT 114 16TH STREET CHARLESTOWN MA 02129 501C3 750000 WHOLE GENOME SEQUENCING NEW YORK STEM CELL FOUNDATION 1995 BROADWAY STE 600 NEW YORK NY 10023 501C3 100000 STEM CELL MOUNT SINAI SCHOOL OF MEDICINE ONE GUSTAVE L LEVY PLACE NEW YORK NY 100296574 501C3 100000 STEM CELL STEM CELL CONSORTIUM UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501C3 100000 EFFECTS OF INHIBITORS OF MONOACYLGLYCEROL LIPASE ON BEHAVIOR AND SYNAPTIC PLASTICITY OF TS65DN MICE, A GENETIC MODEL OF DOWN SYNDROME UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501C3 150000 ELUCIDATION OF THE MECHANISM OF ACTION OF GAMMA SECRETASE MODULATORS MASSACHUSETTS GENERAL HOSPITALHARVARD 114 16TH STREET CHARLESTOWN MA 02129 501(C)(3) 600000 CONTINUATION OF ALZHEIMER'S GENOME PROJECT VASCULAR AMULOID WASHINGTON UNIVERSITY ST LOUIS 660 S EUCLID AVE BOX 8111 ST LOUIS MO 63110 115(1) 100000 THE ROOT OF ALZHEIMER'S DISEASE: PURIFICATION AND CHARACTERIZATION OF AMYLOID-BETA OLIGOMERS FROM THE HUMAN BRAIN WASHINGTON UNIVERSITY ST LOUIS 660 S EUCLID AVE BOX 8111 ST LOUIS MO 63110 115(1) 100000 SLEEP AND TAUOPATHIES: EFFECT OF AN ANTI-TAU ANTIBODYABETA OLIGOMERS IN HUMAN BRAIN MAYO CLINIC 4500 SAN PABLO ROAD JACKSONVILLE FL 32224 501C3 100000 VASCULAR REGENERATION THERAPIES FOR ALZHEIMER'S DISEASE MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 501(C)(3) 100000 DISCOVERY OF ALZHEIMER'S DISEASE BLOOD BIOMARKERS USING PHAGE DISPLAY TECHNOLOGY PART I, LINE 2: AFTER A PRELIMINARY REVIEW OF THE SUBMITTED PROPOSAL BY THE CHAIR OF THE RESEARCH CONSORTIUM, A PROPOSAL MAY BE SENT FOR A SECOND PRELIMINARY REVIEW BY OTHER MEMBERS OF THE RESEARCH CONSORTIUM. IF THOSE PEOPLE DEEM THE PROPOSAL APPROPRIATE FOR FURTHER REVIEW, THE PRESIDENT OF CURE ALZHEIMER'S FUND SENDS THE PROPOSAL TO TWO MEMBERS OF THE SCIENTIFIC ADVISORY BOARD FOR THEIR REVIEWS. QUESTIONS OR CONCERNS BY THE REVIEWERS ARE SENT TO THE PERSON PROPOSING THE PROJECT FOR RESOLUTION. IF THE RESOLUTION IS SATISFACTORY TO THE REVIEWER(S), THE PROPOSAL IS THEN SENT TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS FOR FINAL APPROVAL. AFTER THAT APPROVAL, THE PROPOSAL IS FUNDED WITH THE CONDITIONS THAT THERE BE A MID-TERM REPORT APPROXIMATELY SIX MONTHS FROM THE TIME OF ISSUE INCLUDING PROGRESS AGAINST THE ORIGINAL OBJECTIVES; AND A FINAL REPORT DUE TWELVE MONTHS AFTER THE TIME OF ISSUE INCLUDING RESULTS MEASURED AGAINST OBJECTIVES AND A FULL FINANCIAL REPORT ON THE USE OF THE GRANT FUNDS. A PROJECT CAN BE INTERRUPTED OR RE-DIRECTED AT ANY TIME THE RESEARCH CONSORTIUM OR THE SCIENTIFIC ADVISORY BOARD BELIEVES THE PROJECT IS NOT FULFILLING ITS ORIGINAL INTENT. X 0 0 0 0 0 0 0 0 0 TIMOTHY W ARMOUR PRESIDENT 177015 0 0 0 0 0 0 0 4759 0 181774 0 0 0 PART I, LINE 3 A COMPENSATION COMMITTEE REVIEWS ALL COMPENSATION ANNUALLY. X 19 1437142 AVERAGE HIGH AND LOW 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR AS SOON THEREAFTER AS IS PRACTICAL THROUGH BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11 THE PRESIDENT REVIEWS THE FORM 990 AND PROVIDES COPIES TO THE DIRECTORS BEFORE APPROVING THE FORM FOR SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE PRESIDENT REGULARLY AND CONSISTENTLY MONITORS COMPLIANCE WITH CONFLICTS OF INTEREST BY REQUESTING THAT ALL OFFICERS, DIRECTORS, AND FOUNDERS SIGN AN ANNUAL STATEMENT DISCLOSING ALL INTERESTS THAT MIGHT CONFLICT WITH ANY INTEREST OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST OR AT THE ORGANIZATION'S WEBSITE.